2003 OPEN FORUM Abstracts
DEFECTIVE PERIPHERAL BLOOD T CELL FUNCTION IN COPD DISEASE
PATIENTS IS RESTORED
BY TREATMENT WITH THE IMMUNOMODULATOR CELLMUNE? (AM3).
Reyes E, Prieto A, Monserrat J, Izquierdo JL, Callol L, Lucas P, Álvarez-Sala R, Álvarez-Sala JL, Villarrubia V, Álvarez-Mon M. Departamento de Medicina. Universidad de Alcalá, Madrid, Spain
Chronic obstructive pulmonary disease (COPD) is associated with severe alterations and deficiencies of the immune system. These abnormalities appear to be involved in the predisposition to respiratory infections and in the pathogenesis of the disease. Cellmune treatment is able to normalize defective effector functions of Natural Killer cells and monocytes of COPD patients (Am J Respir Crit Care Med 2001;163:1578-1583). We have investigated the T lymphocyte function of COPD patients and the immunorregulatory effects of Cellmune treatment.
MATERIAL AND METHODS. 70 COPD patients were randomized in a double-blind clinical trial to receive either Cellmune or placebo (3 g/day) orally for 90 consecutive days. 36 non-smoker and 18 ex-smoker sex and age-matched healthy controls were included as reference groups for immunological studies.
RESULTS. Peripheral blood mononuclear cells (PBMC) proliferation in response to the T cell mitogens phytohemagglutinin and anti-CD3+anti-CD28, interferon gamma (IFN) production and number of T lymphocytes secreting this cytokine were significantly decreased in COPD patients with respect both groups of controls. In these COPD patients these parameters were assessed at baseline and at the end of treatment. Treatment with Cellmune restored PBMC proliferative response and IFN production in COPD patients to levels seen in healthy controls. The normalization of the proliferative responses was not related to increases in the numbers of monocytes, CD3+, CD4+, CD8+ cells or any naïve/memory T cell subsets. A normalization of the percentage of IFN secreting T lymphocytes was found in Cellmune arm.
CONCLUSIONS. PBMCs of patients with COPD show clear defects in mitogenic responses to T lymphocyte mitogens and IFN production that were fully restored by Cellmune treatment.